Overview

NBTXR3 With or Without Cetuximab in LA-HNSCC

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.

Phase:

Phase 3

Details

Lead Sponsor:

Nanobiotix

Treatments:

Cetuximab